Novartis Finland
- Company typePrivate
- Founded-
- HeadquartersFinland, Finland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Novartis Finland does
Novartis Finland Oy is the Finnish operating subsidiary of global pharmaceutical company Novartis AG, headquartered in Espoo with approximately 55 employees. The entity functions as a local market-access and commercial arm rather than an independent drug developer: it distributes and supports Novartis's prescription pharmaceutical portfolio across therapeutic areas including oncology, immunology, neurology, cardiovascular, and hematology within the Finnish healthcare system. Its go-to-market is sales-led, combining field sales representatives targeting physicians and hospital pharmacists with digital channels such as the NovartisPro professional portal and the Medhub medical-information platform.
The company's offerings extend beyond product supply into healthcare professional services, including clinical trial participation programs and the Sydänohjelma Polku cardiovascular care-pathway initiative aimed at coordinated heart-patient care. A patient-facing health information portal covers a broad set of disease areas, and the subsidiary maintains ongoing collaborations with patient organizations to support education and advocacy. Revenue is generated through prescription pharmaceutical sales distributed via Finnish pharmacies and healthcare institutions, with pricing and reimbursement governed by the Finnish Medicines Agency (Fimea) and the Social Insurance Institution (Kela). Novartis Finland operates as a wholly-owned subsidiary of Novartis AG, a publicly traded company listed on the New York Stock Exchange, and relies on the parent group's R&D pipeline, regulatory approvals, and global scale for its competitive position.
Novartis Finland firmographics
Firmographics- Name
- Novartis Finland
- Legal name
- Novartis Finland Oy
- Website
- https://novartis.fi
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Novartis Finland industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Novartis Finland is headquartered
LocationHeadquarters
- HQ city
- Finland
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Novartis Finland business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Pharmaceutical Product Sales: Novartis Finland generates revenue through the sale of prescription pharmaceutical products including medicines for oncology, immunology, neurology, cardiovascular diseases, and other therapeutic areas. Products are distributed to healthcare providers and patients through pharmacies and healthcare institutions.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Novartis Finland product offering
Product offeringCore offering
Novartis Finland Oy markets and distributes prescription pharmaceutical products from its global parent Novartis AG across multiple therapeutic areas, including oncology, immunology, neurology, cardiovascular diseases, and hematology. The subsidiary also offers clinical research participation services, a healthcare-professional portal (NovartisPro), the Sydänohjelma Polku cardiovascular care program, and a patient-facing health information portal covering a broad range of conditions.
Product overview
Novartis Finland operates as a subsidiary of the global pharmaceutical company Novartis, offering a portfolio of medicines and healthcare solutions. The company provides NovartisPro, a dedicated platform for healthcare professionals, alongside clinical trial participation services and the Sydänohjelma Polku (Heart Path Program) for cardiovascular patient care. Patient-facing services include a comprehensive health information portal covering therapeutic areas such as oncology, immunology, neurology, cardiology, and hematology. The company focuses on developing innovative treatments for diseases with high patient need, with significant investments in research and development supporting its product portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- NovartisPro A dedicated platform for Finnish healthcare professionals providing access to product information, medical resources, professional development materials, and clinical tools for Novartis medicines.
- Sydänohjelma Polku (Heart Path Program) A cardiovascular care program aimed at providing equitable health outcomes for heart patients in Finland through coordinated care pathways and clinical decision support.
- Kliiniset tutkimukset (Clinical Trials) Clinical research services enabling Finnish healthcare professionals and sites to participate in Novartis-sponsored clinical studies across multiple therapeutic areas.
- Patient Health Information Portal Patient-facing information portal covering multiple therapeutic areas including axial spondylarthritis, atherosclerosis, hematology, hidradenitis suppurativa, immune thrombocytopenia, migraine, multiple sclerosis, myelofibrosis, myeloproliferative diseases, psoriatic arthritis, polycythemia vera, psoriasis, breast cancer, heart failure, and urticaria, aimed at Finnish patients and families.
Companies that use Novartis Finland
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Novartis Finland technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Novartis Finland partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Patient organizationscoreNovartis collaborates with patient organizations around the world to find new ways to improve and extend people's lives. These partnerships support patient support programs, health education, and advocacy initiatives.
Scale indicators1 record
Recent moves3 records
Expansion highlights4 records
Novartis Finland competitors and assessment
Company assessmentDirect peers
- GSK Finland: GSK's Finnish subsidiary selling specialty and primary-care pharmaceuticals, including vaccines, HIV, and oncology. Comparable multinational pharma local-sales entity operating under the same Kela/Fimea reimbursement framework.
- Pfizer Finland: Pfizer's Finnish subsidiary, selling branded prescription pharmaceuticals across oncology, vaccines, and specialty care via field sales and HCP portals. Directly comparable in business model, therapeutic breadth, and operating footprint within Finland.
- Bayer Finland: Bayer's Finnish subsidiary covering pharmaceuticals (cardiology, women's health, oncology) and crop science. Comparable as a multinational pharma subsidiary with field-sales and HCP engagement in Finland.
- MSD Finland (Merck & Co.): MSD's Finnish arm selling branded pharmaceuticals in oncology, vaccines, and specialty care. Highly comparable as a multinational pharma subsidiary operating a similar field-sales and HCP-engagement model in Finland.
- Sanofi Finland: Sanofi's Finnish subsidiary distributing specialty pharmaceuticals in immunology (Dupixent), rare diseases, and vaccines. Comparable business model as a multinational pharma local sales entity.
- AstraZeneca Finland: AstraZeneca's Finnish subsidiary with a strong oncology, cardiovascular, renal, and respiratory specialty pharma portfolio. Comparable in therapeutic breadth, GTM, and reliance on Kela reimbursement.
- Roche Finland: Roche's Finnish subsidiary focused on oncology, hematology, immunology, and neurology specialty pharmaceuticals, distributed via field sales to HCPs and pharmacies. Comparable in therapeutic mix and specialty-pharma GTM motion in Finland.
- AbbVie Finland: AbbVie's Finnish subsidiary focused on specialty pharma in immunology (Humira/Skyrizi/Rinvoq), oncology, and neuroscience. Directly comparable as a specialty-pharma-led multinational subsidiary operating in Finland.
- Eli Lilly Finland: Eli Lilly's Finnish subsidiary selling specialty pharmaceuticals in oncology, diabetes, immunology, and neuroscience. Comparable in business model and specialty-pharma positioning within the Finnish market.
Regional players
- Oriola: One of Finland's leading pharmaceutical wholesalers and distributors, partnering with multinational pharma companies (including Novartis) to distribute products through pharmacies. Comparable as a Finland-specific pharma distribution intermediary, though operating at a different layer of the value chain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Novartis Finland social profiles
Digital presenceNovartis Finland financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novartis Finland leadership team
Management profileNumber of profiles
Profiles1 record
Novartis Finland funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novartis Finland M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novartis Finland
What does Novartis Finland do?
Novartis Finland Oy markets and distributes prescription pharmaceutical products from its global parent Novartis AG across multiple therapeutic areas, including oncology, immunology, neurology, cardiovascular diseases, and hematology. The subsidiary also offers clinical research participation services, a healthcare-professional portal (NovartisPro), the Sydänohjelma Polku cardiovascular care program, and a patient-facing health information portal covering a broad range of conditions.
Is Novartis Finland a public or private company?
Novartis Finland is a private company. It is classified as corporate owned and is currently operating.
When was Novartis Finland founded?
Novartis Finland was founded in -1. It employs 51 to 100 people.
Where is Novartis Finland based?
Novartis Finland is headquartered in Finland, Finland, in the Europe region.
How does Novartis Finland make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Novartis Finland's main competitors?
Direct peers on record are GSK Finland, Pfizer Finland, Bayer Finland, MSD Finland (Merck & Co.), Sanofi Finland, AstraZeneca Finland, Roche Finland, AbbVie Finland and Eli Lilly Finland. Oriola is listed as a regional player.
Does Novartis Finland have an API?
No public API is recorded for Novartis Finland.
What industry is Novartis Finland in?
Novartis Finland's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.